Dermavant Showcases VTAMA® Cream Phase 3 Results for Atopic Dermatitis in Diverse Populations at 2024 AAD Meeting

Dermavant Sciences, a biopharmaceutical firm specializing in immuno-dermatology, has announced that it will present new clinical data on VTAMA® (tapinarof) cream, 1%, at the 2024 American Academy of Dermatology Annual Meeting. The data will focus on the treatment of atopic dermatitis in both adults and children over two years old. The cream is a new type of aryl hydrocarbon receptor agonist, designed for daily use without the need for steroids. It is aesthetically pleasing and is currently approved in the U.S. for treating plaque psoriasis in adults. The ADORING Phase 3 trials are evaluating its potential for atopic dermatitis treatment.
The meeting will feature four poster presentations, two of which will be oral presentations, showcasing the clinical findings. The presentations will cover patient-reported outcomes, including quality of life and symptom assessments, as well as the interim analysis of the long-term extension trial ADORING 3. Data on the efficacy of the cream in patients with different skin types and races will also be presented, along with its tolerability in sensitive skin areas.
VTAMA cream has been reported to have common adverse reactions such as folliculitis, nasopharyngitis, contact dermatitis, headache, itching, and influenza. Dermavant encourages reporting of side effects to the FDA. Atopic dermatitis, also known as eczema, is a prevalent skin condition affecting over 26 million people in the U.S. and up to 10% of adults globally. It is particularly common in children and can cause significant social and emotional distress due to its visibility and discomfort.
Dermavant Sciences, a subsidiary of Roivant Sciences, aims to develop therapies for high unmet medical needs in immuno-dermatology. The company's pipeline includes products for plaque psoriasis, atopic dermatitis, and other immunological and inflammatory diseases. Dermavant is also developing DMVT-506, a next-generation aryl hydrocarbon receptor agonist with potential for various administration routes.